{'fraction_non_alphanumeric': 0.025, 'fraction_numerical': 0.0035714285714285713, 'mean_word_length': 5.6, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of a pediatric patient with MET‐amplified signet ring cell adenocarcinoma of the stomach with crizotinib

Signet ring cell adenocarcinoma (SRCA) of the stomach is an aggressive form of gastric cancer that correlates with an advanced disease stage and poor overall survival in pediatric patients.1–3 Herein, we report a case of stage IV SRCA of the stomach with mesenchymal epithelial transition (MET) amplification that responded to crizotinib, a dual anaplastic lymphoma receptor tyrosine kinase (ALK)/MET inhibitor, and conduct a literature review.